Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study

被引：0
|
作者：
Meletios Dimopoulos
Michael Wang
Vladimir Maisnar
Jiri Minarik
William Bensinger
Maria-Victoria Mateos
Mihaela Obreja
Julie Blaedel
Philippe Moreau
机构：
[1] National and Kapodistrian University of Athens,School of Medicine
[2] The University of Texas MD Anderson Cancer Center,undefined
[3] Faculty Hospital and Medical Faculty of Charles University in Hradec Kralove,undefined
[4] University Hospital Olomouc,undefined
[5] Medical Faculty of Palacky University Olomouc,undefined
[6] Fred Hutchinson Cancer Research Center,undefined
[7] Hospital Clinico Universitario de Salamanca-IBSAL,undefined
[8] Amgen,undefined
[9] Inc.,undefined
[10] University of Nantes,undefined
来源：
Journal of Hematology & Oncology | / 11卷
关键词：
Clinical research; Clinical trials; Multiple myeloma; Myeloma therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
    Minarik, Jiri
    Pika, Tomas
    Radocha, Jakub
    Jungova, Alexandra
    Straub, Jan
    Jelinek, Tomas
    Pour, Ludek
    Pavlicek, Petr
    Mistrik, Martin
    Brozova, Lucie
    Krhovska, Petra
    Machalkova, Katerina
    Jindra, Pavel
    Spicka, Ivan
    Plonkova, Hana
    Stork, Martin
    Bacovsky, Jaroslav
    Capkova, Lenka
    Sykora, Michal
    Kessler, Petr
    Stejskal, Lukas
    Heindorfer, Adriana
    Ullrychova, Jana
    Skacel, Tomas
    Maisnar, Vladimir
    Hajek, Roman
    BMC CANCER, 2021, 21 (01)
  • [32] TWO COST-EFFECTIVENESS ANALYSES OF THE USE OF CARFILZOMIB IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE VERSUS LENALIDOMIDE PLUS DEXAMETHASONE AND CARFILZOMIB PLUS DEXAMETHASONE VERSUS BORTEZOMIB PLUS DEXAMETHASONE FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA IN COLOMBIA
    van Beurden-Tan, C.
    Forero, J.
    Coggia, A.
    Bustos Marquez, M. C.
    VALUE IN HEALTH, 2019, 22 : S480 - S480
  • [33] Lenalidomide and Low Dose Dexamethasone Plus Elotuzumab or Carfilzomib for Relapsed or Refractory Multiple Myeloma: A Comparison of Progression-Free Survival with Reconstructed Individual Participant Data
    Li, Shuo
    Meng, Xiang-Yu
    Maman, Souraka Tapara Dramani
    Xiao, Yong-Nong
    Li, Sheng
    BIOMED RESEARCH INTERNATIONAL, 2018, 2018
  • [34] Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391)
    Avet-Loiseau, Herve
    Fonseca, Rafael
    Siegel, David
    Dimopoulos, Meletios A.
    Spicka, Ivan
    Masszi, Tamas
    Hajek, Roman
    Rosinol, Laura
    Goranova-Marinova, Vesselina
    Mihaylov, Georgi
    Maisnar, Vladimir
    Mateos, Maria -Victoria
    Wang, Michael
    Niesvizky, Ruben
    Oriol, Albert
    Jakubowiak, Andrzej
    Minarik, Jiri
    Palumbo, Antonio
    Bensinger, William
    Kukreti, Vishal
    Ben-Yehuda, Dina
    Tonda, Margaret
    Obreja, Mihaela
    Moreau, Philippe
    BLOOD, 2015, 126 (23)
  • [35] Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial
    Jacobus, Susanna J.
    Cohen, Adam D.
    Weiss, Matthias
    Callander, Natalie Scott
    Singh, Avina A.
    Parker, Terri L.
    Menter, Alex R.
    Yang, Xuezhong
    Parsons, Benjamin Marshall
    Kumar, Pankaj
    Kapoor, Prashant
    Rosenberg, Aaron Seth
    Zonder, Jeffrey A.
    Faber, Edward Anthony
    Lonial, Sagar
    Richardson, Paul G.
    Orlowski, Robert Z.
    Wagner, Lynne I.
    Rajkumar, S. Vincent
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (18)
  • [36] Cost per Progression Free Survival (PFS) of Daratumumab, Elotuzumab, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (DRd, ERd, KRd, IRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Santana, Pamela
    Saad, Ricardo
    Kolanian, Adrielle
    Fioratti, Cyntia
    Junqueira, Marcela
    Decimoni, Tassia
    BLOOD, 2019, 134
  • [37] A phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone (QUAD) in relapsed and/or refractory multiple myeloma (MM).
    Vesole, David H.
    Siegel, David Samuel DiCapua
    Richter, Joshua Ryan
    McNeill, Ann
    Anand, Palka
    Bednarz, Urszula
    Ivanovski, Kristin
    McBride, Laura
    Raucci, Laura
    Batra, Veena
    Aleman, Adolfo
    Sims, Taliah
    Guerrero, Laura
    Smith, Judith
    Mato, Anthony R.
    Bilotti, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [38] Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study
    Biran, Noa
    Siegel, David
    Berdeja, Jesus G.
    Raje, Noopur
    Cornell, Robert Frank
    Alsina, Melissa
    Kovacsovics, Tibor
    Fang, Belle
    Kimball, Amy S.
    Landgren, Ola
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (07) : 794 - 802
  • [39] Longer Duration of Treatment and Maintenance of Best Response with Lenalidomide and Dexamethasone Prolongs Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma
    Miguel, Jesos F. San
    Dimopoulos, Meletios A.
    Stadtmauer, Edward A.
    Rajkumar, S. Vincent
    Siegel, David
    Bravo, Marie-Laure
    Olesnyckyj, Marta
    Knight, Robert D.
    Zeldis, Jerome B.
    Harousseau, Jean-Luc
    Weber, Donna M.
    BLOOD, 2008, 112 (11) : 1269 - 1269
  • [40] Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma
    Dimopoulos, M. A.
    Hussein, M.
    Swern, A. S.
    Weber, D.
    LEUKEMIA, 2011, 25 (10) : 1620 - 1626
12345